Skip to main content
OpenTrials
Completed

NCT Number: NCT01750502

The Clinical Diagnosis Meaning of MIF in Coronary Heart Disease

Macrophage migration inhibitory factor (MIF) is a pleiotropic cytokine that promote the inflammatory response.In animal studies, it has been found that MIF is released in the ischaemic heart, promoting glucose uptake and protecting the heart from ischaemia-reperfusion injury.The MIF concentration, influenced by age and myocardial ischemia, have different impact on myocardial functional recovery after ischemia.Therefore, the purpose of this experiment is to study the clinical significance of MIF in patients with coronary heart disease.

Completed

Looking for future studies?

Notify Me

Key information

Age range

20 year–90 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Second Hispital of Wenzhou Medical College

Wenzhou, Zhejiang, 325000, China

About this study

MIF is a pleiotropic cytokine that promote the inflammatory response. MIF is expressed in several cell types,including monocytes/macrophages, vascular smooth muscle and cardiomyocytes, and is released on stimulation from pre-formed storage pools. A foreign study reported that MIF had demonstrated to offer protection from I/R-injury by activating adenosine monophosphate-activated protein kinase (AMPK) and inhibiting c-Jun Nterminal kinase (JNK)-induced apoptosis of cardiomyocytes. In addition, animal experiments showed that MIF was reduced in aged heart compared with young heart. Coronary heart disease is a chronic ischemic disease, in which MIF may play as a protective factor during the whole procedure.

We observed individuals who will be taking coronary angiography during the hospitalization. Individuals will be assigned to coronary-artery-disease group, which included acute coronary syndromes and stable ischemic heart disease, or non-coronary-artery-disease group, according to coronary angiography. All participants will be extracted 3ml blood sample 5 minutes before coronary angiography. Coronary-artery-disease group will be taken another two blood samples, 5 minutes after the opening of the balloon and 5 minutes after the stents have been implanted, respectively.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Control group:

  • enroll individuals who confirmed by coronary angiography without coronary heart
  • The age between 20 and 80 years old.
  • Alanine aminotransferase(ALT):10-55U/L, Aspartate aminotransferase(AST):0-60U/L
  • Glucose(GLU-S):3.9-6.1mmol/L
  • Triglycerides(TRIG):0.56-1.7mmol/L, cholesterol(CHOL):3.1-5.2mmol/L, High density lipoprotein(HDL):0.78-1.96mmol/L, High density lipoprotein(LDL):2.07-3.1mmol/L

Experimental group:

  • enroll individuals who confirmed by coronary angiography for coronary heart
  • The age between 20 and 80 years old.
  • ALT:10-55U/L,AST:0-60U/L
  • GLU-S:3.9-6.1mmol/L
  • TRIG:0.56-1.7mmol/L,CHOL:3.1-5.2mmol/L,HDL:0.78-1.96mmol/L,LDL:2.07-3.1mmol/L

Exclusion criteria

  • Inflammatory diseases,such as rheumatoid arthritis,sepsis,asthma and acute respiratory distress syndrome.
  • Diabetes

Treatment and study plan

Primary outcomes

  1. Comparison Between Coronary-artery-disease Group and Non-coronary-artery-disease Group on MIF Concentration

    Time frame: Before surgery 5 minutes

    Participants will be extracted 3ml blood before surgery 5 minutes,detection MIF concentration on two groups.We hypothesis that the experimental group will be higher than control group.

Secondary outcomes

  1. Comparison the Change of MIF Before and After Percutaneous Coronary Intervention (PCI) at the Patients Who Are Acute Coronary Syndromes and Stable Ischemic Heart Disease

    Time frame: 3 times including before surgery 5 minutes, 5 minutes after the opening of the balloon and after surgery 5 minutes

    Percutaneous Coronary Intervention are extracted 3 times including before surgery 5 minutes , 5 minutes after the opening of the balloon and after surgery 5 minutes ,and detection MIF concentration .

Other outcomes

  1. Comparison With MIF-173G/C Genotypes of CHD Patients and Controls.

    Time frame: Before surgery

  2. Comparison of MIF-173G/C Alleles of CHD Patients and Controls.

    Time frame: Before surgery

Sponsors and collaborators

Lead sponsor

Wenzhou Medical University

Other

Registry information

Official study title

MIF Gene Polymorphism in Coronary Heart Disease:Clinical Meaning

Important dates

Study start
2012
Primary completion
2013
Study completion
2013
First posted
Dec 17, 2012
Registry last updated
Mar 4, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.